M. Dubay

发表

Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.

C. Maroun, M. Fournel, J. Besterman, 2010 .

Flavopiridol Induces Gj Arrest with Inhibition of Cyclin-dependent Kinase ( CDK ) 2 and CDK 4 in Human Breast Carcinoma Cells

E. Sausville, B. Carlson, P. Worland, 2006 .

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

M. Carducci, L. Siu, A. Kalita, 2008, Clinical Cancer Research.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

J. Byrd, S. Kambhampati, K. Blum, 2009, British journal of haematology.

A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma

P. Mclaughlin, R. Martell, L. Fayad, 2007 .

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

A. Yang, H. Kantarjian, G. Garcia-Manero, 2007 .

Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC

M. Carducci, L. Siu, A. Kalita, 2008 .

Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.

S. Wick, L. Brizuela, M. Dubay, 1995, Oncogene.

Structure-activity relationship studies of flavopiridol analogues.

P. Worland, L. Brizuela, K. Pal, 2000, Bioorganic & medicinal chemistry letters.

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

E. Sausville, B. Carlson, P. Worland, 1996, Cancer research.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

M. Robert, A. Macleod, A. Vaisburg, 2008, Bioorganic & medicinal chemistry letters.

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

P. Mclaughlin, A. Younes, R. Martell, 2007 .

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

R. Bociek, P. Mclaughlin, A. Younes, 2007 .

Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation.

S. Wick, L. Brizuela, X Xu, 1999, Biochemistry.

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

M. Robert, Nancy Z. Zhou, S. Raeppel, 2009, Bioorganic & medicinal chemistry letters.

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Sylvain Lefebvre, M. Robert, Nancy Z. Zhou, 2009, Bioorganic & medicinal chemistry letters.

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

J. Issa, A. Yang, H. Kantarjian, 2006 .

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.